Haloperidol decanoate and long-acting injectable risperidone: Subjective experience of outpatients with schizophrenia;Aloperidolo decanoato e risperidone iniettabile a rilascio prolungato: Esperienza soggettiva di pazienti schizofrenici ambulatoriali

Italian Journal of Psychopathology

Volumn 16, Issue 3, 2010, Pages 299-304

  Dalmotto, Marinella ^a   Pirfo, E ^a  

^a ASL 2   (Italy)

Author keywords

Haloperidol decanoate; Long acting injectable risperidone; Subjective experience

Indexed keywords

HALOPERIDOL DECANOATE; LONG ACTING DRUG; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; HUMAN; PATIENT ASSESSMENT; SCHIZOPHRENIA;

EID: 78650409770     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Awad AG, Hogan TP, Voruganti LNP, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacology 1995;10:123-32.
2. Pereira S., Pinto R. A survey of attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997;95:464-8.
3. Goldbeck R, Tomlinson S, Bouch J. Patient's knowledge and views of their depot neuroleptic medication. Psychiatric Bull 1999;23:467-70.
4. Walburn J, Gray K, Quaraishi S, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7.
5. Rossi A, Stratta P, Arduini L. La compliance al trattamento farmacologico con antipsicotici. Ital J Psychopathol 2002;8:391-400. (Pubitemid 36330178)
6. Larsen EB, Gerlach J. Subjective experience of treatment, side effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996;93:381-8. (Pubitemid 26189163)
7. Citrome L. Patient perspectives in the development and use of long acting anti psychotics in schizophrenia: focus on olanzapine long acting injection. Patients Prefer Adherence 2009;3:345-55.
8. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better? J Clin Psychiatry 2003;64:1308-15.
9. McEvoy JP. Risks versus benefits of different types of long acting injectable antipsychotics. J Clin Psychiatry 2006;67:15-8.
10. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neurosychopharmacol 1998;8:55-66.
11. Chue P. Long acting risperidone injection: efficacy, safety and cost effectiveness of the first long acting atypical antipsychotic. Neuropsichiatr Dis Treat 2007;3:13-39.
12. Moller HJ. Long acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007;67:1541-66.
13. Patel MX, Nikolau V, David AS. Psychiatrists' attitudes to maintence medication for patients with schizophrenia. Psychol Med 2003;33:83-9.
14. Patel MX, David AS. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Nur 2005;12:237-44.
15. Jaeger M, Rossler W. Attitude towards long-acting depot antipsychotics: a survey of patiens, relatives and psychiatrists. Psych Researc 2010;175:58-62.
16. Lasser RA, Bossie CA, Garabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotic experience significant improvement following treatment with long acting risperidone. Eur Psichiatry 2004;19:219-25.
17. First BM, Spitzer RL, Gibbon M, et al. Sructured Clinical Interview for DSM IV Axis I Disorder (SCID I). Versione Italiana di Mazzi F, De Girolamo G, Lussetti M, et al. Firenze: Giunti Organizzazioni Speciali 2007.
18. Conti L. Repertorio delle scale di valutazione in psichiatria. Tomo III. Firenze: SEE 1999, pp. 1661-5.
19. Conti L. Repertorio delle scale di valutazione in psichiatria. Tomo I. Firenze: SEE 1999, pp. 359-64.
20. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy? J Neuro Rx 2004;1:341-7.
21. Awad AG, Voruganti LNP. New antipsychotic, compliance, quality of life and subjective tolerability- are patients better of? Canadian J Psychiatry 2004;49:297-9.
22. Moller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long acting injectable in patients treated with various antipsychotic therapies. International Clin Psychopharmacology 2005;20:121-30. (Pubitemid 40571509)
23. Rocca P, Crivelli B, Marino F, et al. Correlation of attitudes toward antipsychotic drugs with insight and objective psychopatology in schizophrenia. Comp Psychiatry 2008;49:170-6.
24. National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the treatment of Schizophrenia. Technology Appraisal Guidance 43. London: NICE 2002.
25. Niolu C, Siracusano A. Discontinuità psicofarmacologica e aderenza. Roma: Il Pensiero Scientifico Editore 2005.
26. Giannelli A, Rabboni M. I neurolettici long acting nella terapia integrata delle psicosi. Pisa: Pacini Editore 1997.